Dementia is one of the leading causes of death and disability in older population. Previous reports have shown that antidementia medications are associated with longer survival; nonetheless, the prevalence of their use and the compliance with them are quite different worldwide. There is hardly any available information about the pharmacoepidemiology of these drugs in the Eastern-European region; we aimed to analyze the use of cholinesterase inhibitors (ChEis) for the treatment of dementia to provide real-life information from the Eastern European region. All medical and medication prescription reports of the in- and outpatient specialist services collected in the NEUROHUN database in Hungary were analyzed between 2013 and 2016. Survival, adherence, and persistence values were calculated. 8803 patients were treated with ChEis during the study period, which was only 14.5% of the diagnosed demented patients. The survival of treated patients (more than 4 years) was significantly longer than patients without ChEi treatment (2.50 years). The best compliance was observed with rivastigmine patch. Choosing the appropriate medication as soon as possible after the dementia diagnosis may lead to increased life expectancy.

痴呆症是导致老年人口死亡和残疾的主要原因之一。以前的报告表明，抗痴呆药物与更长的生存期有关；然而，它们的使用流行程度和对它们的遵守情况在世界范围内大不相同。在东欧地区几乎没有关于这些药物的药物流行病学的任何可用信息；我们旨在分析使用胆碱酯酶抑制剂 (ChEis) 治疗痴呆症，以提供来自东欧地区的真实信息。分析了 2013 年至 2016 年间在匈牙利 NEUROHUN 数据库中收集的所有住院和门诊专科服务的医疗和药物处方报告。计算了生存率、依从性和持久性值。在研究期间，8803 名患者接受了 ChEis 治疗，仅占确诊痴呆患者的 14.5%。接受治疗的患者（超过 4 年）的生存期明显长于未接受 ChEi 治疗的患者（2.50 年）。使用卡巴拉汀贴剂观察到最佳依从性。在痴呆症诊断后尽快选择合适的药物可能会增加预期寿命。